The super-effectiveness of Morr-F with finasteride in restoring hair growth in men is due to its combination with minoxidil 5%. This is the first attempt to combine the effectiveness of Minoxidil 5% with the antiandrogenic properties of Propecia (Finasteride). Morr-F is a blend of these two active ingredients. According to the manufacturer, the drug MORR-F is not only more effective than minoxidil and finasteride separately, but also allows you to significantly delay the stage of regression when the application is canceled. That is, the effect of MORR-F is much longer!
General information about Minoxidil 5% with Finasteride Morr-F
Morr Forte with Finasteride is manufactured by Halcyon Labs Pvt. Ltd. and is marketed internationally as a brand of a well-known Indian pharmaceutical company Intas Pharmaceuticals Ltd. (India). Intas Pharmaceuticals Ltd. has an international GMP (Good Manufacturing Practice) certificate. GMP certificate - evidence of a high level of production and quality of manufactured drugs.
Founded in the early 70s of the last century Intas Pharmaceuticals Ltd. has become one of the leaders in the pharmaceutical market in India. From the very beginning, Intas Pharmaceuticals Ltd. has set the development and production of drugs for the treatment of diseases in the field of gastroenterology and the cardiovascular system among the priority tasks. Intas Pharmaceuticals Ltd. has achieved significant success in the development and production of cancer, diabetic, antiviral, hormonal and other drugs. In 2007, the production of the company received accreditation of the US FDA. This suggests that the company's drugs meet the highest requirements of American standards. The quality of the products is also confirmed by other organizations such as MHRA, TGA, ANVISA and MCC. The company currently supplies its drugs to 42 countries around the world.
MORR-F solution containing minoxidil and finasteride, when applied topically, should stimulate hair growth in individuals with androgenetic alopecia (male pattern baldness).
Chemically, minoxidil is 2,4-diamino-6-piperidinopyrimidine-3-oxide.
Finasteride, a synthetic 4-azasteroid compound, is a specific inhibitor of steroid type II 5-alpha reductase, which is an intracellular enzyme that regulates the conversion of testosterone to 5-alpha dihydrotestosterone (DHT).
When applied topically, minoxidil solution for external use has been shown to stimulate hair growth in individuals with androgenetic alopecia (male pattern baldness). Although the exact mechanisms of action of minoxidil in the treatment of androgenetic alopecia are not known, there may be several ways this drug can stimulate hair growth. These include:
- Vasodilation of the microvasculature around the hair follicles, which enhances hair growth;
- Direct stimulation of hair follicle cells, which induces them to enter the proliferative phase: follicles in the resting phase (telogen) enter the active phase (anagen);
- Disruption of the effect of androgens on genetically predisposed hair follicles: Minoxidil can interfere with androgen metabolism in the scalp, suppressing the ability of androgens to act on hair follicles.
In men with male pattern hair loss (androgenetic alopecia), the bald scalp has smaller hair follicles than normal scalp, and the amount of DHT is increased. The use of finasteride in such men reduces the concentration of DHT in the scalp, which contributes to the manifestation of the therapeutic effect of this drug. Considering this mechanism of action, finasteride disrupts the most important pathway for the development of androgenetic alopecia in genetically predisposed patients.
Clinical studies conducted with minoxidil and finasteride solution show that the expected stimulation of hair growth may require application of the drug for 4 months or more. The duration of the onset of drug action and the degree of its activity may differ among patients. Although discontinuation of topical minoxidil solution returns to baseline after 3-4 months, it is believed that this should not be expected if MORR-F is used, as finasteride has an additional positive effect.
The difference between Morr-F and finasteride from other similar drugs (Essengen Plus, Dualgen Plus, etc.)
There are still few companies producing minoxidil with finasteride. And therefore, a comparative study can be carried out between them. MORR-F has a number of features compared to Essengen Plus and Dualgen Plus US companies. Essengen Plus contains less finasteride than MORR-F. Dualgen Plus includes additives that enhance its effectiveness, but are not always very pleasant to the hair after application (feeling of a little messy). MORR-F contains pure minoxidil and is therefore more pleasant to apply. Plus, MORR-F is cheaper. Therefore, the final choice of drugs is a matter of your taste. You can also combine them. For example, when going to work in the morning, apply MORR-F to maintain the look and feel of clean hair, and use Dualgen Plus in the evening.
Packaging form, composition and dosage of Minoxidil 5% with Finasteride Morr-F
MORR-F comes in lotion form. One bottle contains 60 ml of the drug and is designed for 1 month of use.
MORR-F kit includes pipette and spray.
Each ml of solution contains:
- Minoxidil IP (International Pharmacopoeia) - 5% (by weight)
- Finasteride USP (United States Pharmacopoeia) - 0.1% (w/w)
- IP isopropyl alcohol (International Pharmacopoeia) - quantum satis (medical therm: how much you need) up to 1 ml
Indications for the use of Minoxidil 5% with Finasteride Morr-F
MORR-F is used to treat androgenetic alopecia (male pattern baldness) in men aged from 18 to 60 years old. Not for use by women.
Warnings and special instructions for using Minoxidil with Finasteride Morr-F
Some absorption of minoxidil from the skin surface creates the possibility of developing systemic effects such as tachycardia, angina pectoris and edema, and an increased likelihood of orthostatic hypotension caused by guanethidine. Patients should be monitored dynamically to identify possible systemic effects of minoxidil. If systemic side effects appear, the drug should be discontinued. If necessary, diuretic drugs should be used to treat fluid retention and edema. Control of tachycardia and angina pectoris is possible with the prescription of drugs from the group of beta-blockers or other inhibitors of the activity of the sympathetic nervous system. Despite the fact that percutaneous absorption of finasteride is not expected, its development may lead to a decrease in serum DHT levels and the appearance of systemic side effects, such as decreased libido, erectile dysfunction, ejaculation disorders, swelling or tenderness of the mammary glands and pain in the testicular area ... Patients should be monitored dynamically to detect such systemic effects. Particular attention is required for patients with impaired liver function, since the active metabolism of finasteride occurs in the liver.
Pregnancy and Lactation: MORR-F solution should not be used by pregnant or lactating women. Due to the ability of type II 5-alpha reductase inhibitors to suppress the conversion of testosterone to DHT, when administered to pregnant women, the drug can cause abnormalities in the development of the external genitalia in male fetuses.
Childhood: The safety and efficacy of MORR-F in patients under 18 years of age has not been established.
Use in patients with concomitant cardiovascular disease: Minoxidil Topical Solution should not be used in patients with known concurrent coronary artery disease, cardiac arrhythmias, congestive heart failure, or valvular heart disease. Patients with hypertension, including those receiving antihypertensive drugs, should be closely monitored. If necessary, it is necessary to correct the treatment. If the patient has any other cardiovascular disease, MORR-F should be used with caution.
Elderly use: No studies have been performed with people over the age of 60. Therefore, the safety and efficacy of MORR-F has not been identified in these patients.
How to use Minoxidil 5% with Finasteride Morr-F
MORR-F Topical Solution, in a total amount of 1 ml, should be applied twice daily to thinning scalp areas starting from the center of the affected area. Regardless of the size of the affected area, this dose must be used. The total daily dose of the drug should not exceed 2 ml. MORR-F Topical Solution should only be applied to completely dry hair and scalp.